Management of relapsed multiple myeloma after autologous stem cell transplant

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 5, 2015, Pages 793-798

  Holstein, Sarah A ^a   Richardson, Paul G ^b   Laubach, Jacob P ^b   McCarthy, Philip L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Monoclonal antibody; Multiple myeloma salvage autologous stem cell transplant; Relapsed refractory; Salvage allogenic stem cell transplant

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; BROMODOMAIN INHIBITOR; CARFILZOMIB; CYCLOPHOSPHAMIDE; DACETUZUMAB; DARATUMUMAB; DEXAMETHASONE; ELOTUZUMAB; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INDATUXIMAB RAVTANSINE; ISATUXIMAB; IXAZOMIB; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; MONOCLONAL ANTIBODY; OPROZOMIB; PANOBINOSTAT; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; ROMIDEPSIN; SALINOSPORAMIDE A; SILTUXIMAB; THALIDOMIDE; UNINDEXED DRUG; VORINOSTAT; IMMUNOLOGIC FACTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; HUMAN; INTERMETHOD COMPARISON; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; ANALOGS AND DERIVATIVES; AUTOGRAFT; CASE REPORT; MALE; MIDDLE AGED; RECURRENT DISEASE; STEM CELL TRANSPLANTATION;

AUTOGRAFTS; DEXAMETHASONE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTEASOME INHIBITORS; RECURRENCE; STEM CELL TRANSPLANTATION; THALIDOMIDE;

EID: 84928214227     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.12.026     Document Type: Review

References (45)

1. Alegre A., Granda A., Martinez-Chamorro C., et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica 2002, 87:609-614.
2. Lenhoff S., Hjorth M., Turesson I., et al. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006, 91:1228-1233.
3. Zamarin D., Giralt S., Landau H., et al. Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation. Bone Marrow Transplant 2013, 48:419-424.
4. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. NEngl J Med 2012, 366:1770-1781.
5. Attal M., Lauwers-Cances V., Marit G., et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. NEngl J Med 2012, 366:1782-1791.
6. Palumbo A., Cavallo F., Gay F., et al. Autologous transplantation and maintenance therapy in multiple myeloma. NEngl J Med 2014, 371:895-905.
7. Sonneveld P., Schmidt-Wolf IG., van der Holt B., et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. JClin Oncol 2012, 30:2946-2955.
8. Morgan G.J., Walker B.A., Davies F.E. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012, 12:335-348.
9. Keats J.J., Chesi M., Egan J.B., et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012, 120:1067-1076.
10. Shah J.J., Orlowski R.Z., Alexanian R., et al. Phase I trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed/refractory multiple myeloma. ASH Annu Meet Abstr 2010, 116:1948.
11. Shah J.J., Orlowski R.Z., Thomas S.K., et al. Final results of a phase I/II trial of the combination of concurrent lenalidomide, thalidomide and dexamethasone in patients with relapsed and/or refractory myeloma. Blood (ASH Annual Meeting Abstracts) 2012, 120:75.
12. National Comprehensive Cancer Network. Multiple myeloma (version 2.2015). Available at: Accessed October 9,2014. http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.
13. Gonsalves W.I., Gertz M.A., Lacy M.Q., et al. Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplant 2013, 48:568-573.
14. Olin R.L., Vogl D.T., Porter D.L., et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009, 43:417-422.
15. Patriarca F., Einsele H., Spina F., et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant 2012, 18:617-626.
16. Krivanova A., Hajek R., Krejci M., et al. Second autologous transplantation for multiple myeloma patients relapsing after the first autograft-a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group. Onkologie 2004, 27:275-279.
17. Elice F., Raimondi R., Tosetto A., et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006, 81:426-431.
18. Alvares C.L., Davies F.E., Horton C., et al. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006, 91:141-142.
19. Burzynski J.A., Toro J.J., Patel R.C., et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymph 2009, 50:1442-1447.
20. Fenk R., Liese V., Neubauer F., et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymph 2011, 52:1455-1462.
21. Jimenez-Zepeda V.H., Mikhael J., Winter A., et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012, 18:773-779.
22. Shah N., Ahmed F., Bashir Q., et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012, 118:3549-3555.
23. Chow A.W., Lee C.H., Hiwase D.K., et al. Relapsed multiple myeloma: who benefits from salvage autografts?. Intern Med J 2013, 43:156-161.
24. Michaelis L.C., Saad A., Zhong X., et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant 2013, 19:760-766.
25. Thompson P.A., Prince H.M., Seymour J.F., et al. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant 2011, 46:764-765.
26. Doo N.W., Thompson P.A., Prince H.M., et al. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leuk Lymph 2013, 54:1465-1472.
27. Cook G., Williams C., Brown J.M., et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15:874-885.
28. Wirk B., Byrne M., Dai Y., Moreb J.S. Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation. JClin Med Res 2013, 5:174-184.
29. Qazilbash M.H., Saliba R., De Lima M., et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006, 106:1084-1089.
30. Mehta J., Tricot G., Jagannath S., et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?. Bone Marrow Transplant 1998, 21:887-892.
31. Freytes C.O., Vesole D.H., LeRademacher J., et al. Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplant 2014, 49:416-421.
32. de Lavallade H., El-Cheikh J., Faucher C., et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008, 41:953-960.
33. Laubach J.P., Voorhees P.M., Hassoun H., et al. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol 2014, 7:97-111.
34. Laubach J.P., Mahindra A., Mitsiades C.S., et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009, 23:2222-2232.
35. Garderet L., Iacobelli S., Moreau P., et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. JClin Oncol 2012, 30:2475-2482.
36. Knopf K.B., Duh M.S., Lafeuille M.H., et al. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymph Myeloma Leuk 2014, 14:380-388.
37. Madan S., Lacy M.Q., Dispenzieri A., et al. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood 2011, 118:1763-1765.
38. Kumar S.K., Therneau T.M., Gertz M.A., et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004, 79:867-874.
39. Kumar S.K., Lee J.H., Laheurta J.J., et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012, 26:149-157.
40. Richardson P.G., Lonial S., Jakubowiak A.J., et al. Monoclonal antibodies inthe treatment of multiple myeloma. Br J Haematol 2011, 154:745-754.
41. San-Miguel J.F., Hungria V.T., Yoon S.S., et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014, 15:1195-1206.
42. Lonial S., Vij R., Harousseau J.L., et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. JClin Oncol 2012, 30:1953-1959.
43. Zonder J.A., Mohrbacher A.F., Singhal S., et al. Aphase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012, 120:552-559.
44. Martin T.G., Strickland S.A., Glenn M., et al. SAR650984, a CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies-data from a dose-escalation phase I study. Blood (ASH Annual Meeting Abstracts) 2013, 122:284.
45. Plesner T., Lokhorst H., Gimsing P., et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma-data from a dose-escalation phase I/II study. Blood (ASH Annual Meeting Abstracts) 2012, 120:73.